JOHNSON & JOHNSON
CIK
200406
Location
NEW BRUNSWICK, NJ
Portfolio Value
Small
$495,754,388
Diversification
Moderately concentrated
Filing Date
Global Rank
#2,579
/ 7,976
▲ 511
Top Industry
Biotechnology
90.5%
3Y Alpha vs SPY
+8.8%
Period ended 9 months ago
Filed Mar 18, 2026 · 3mo
17 quarters · since Sep 2021
Clone Performance
Jun 2023–Jun 2026 · vs SPYHypothetical growth of cloning every reported 13F position and rebalancing on each filing, indexed to the same start.
Cloned portfolio
+117.6%
SPY
+76.3%
Annualised alpha
+8.8%
Max drawdown
−43.4%
Estimate. 13F holdings are quarter-lagged and long-only, so the clone rebalances about 45 days after each period end — when the filing becomes public — and excludes options and short positions. Past performance does not predict future results.
Portfolio Concentration
14 positions · as of Sep 30, 2025 · Δ vs Jun 30, 2025Top Position
32.8%
−8.2 pts
Top 5
82.6%
+3.1 pts
Top 10
98.8%
+0.3 pts
HHI
1,881
Moderately concentrated−294
Portfolio Trend
17 quarters · across all stocks
Sector Breakdown
As of Sep 30, 2025| Sector | % Portfolio | Value |
|---|---|---|
| Healthcare | 100.0% | $495,754,388 |
Last Quarter's Activity
Export CSVAdded To
Positions the filer increasedNo qualifying positions this quarter.
Trimmed
Positions the filer reduced
1 positions
| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| RAPP | Rapport Therapeutics, Inc. | −713,534 | 1,784,517 | $53,000,154 | |
| No positions match the current search. | |||||
New Positions
Positions the filer opened this quarter
1 positions
| Ticker | Company | Shares | Value | Open |
|---|---|---|---|---|
| LYEL | Lyell Immunopharma, Inc. | 54,887 | $891,364 | |
| No positions match the current search. | ||||
Sold Out
Positions the filer fully exitedNo qualifying positions this quarter.
14 positions ·
$495,754,388 total
· as of Sep 30, 2025
| Ticker | Company | Type | Shares | Value (USD) | % of Portfolio | History |
|---|---|---|---|---|---|---|
| PTGX |
Protagonist Therapeutics, Inc
Healthcare
|
Held | 2,449,183 | $162,699,226 | 32.82% | |
| NBTX |
Nanobiotix S.A.
Healthcare
|
Held | 5,623,816 | $106,233,884 | 21.43% | |
| MGTX |
MeiraGTx Holdings plc
Healthcare
|
Held | 6,641,064 | $54,655,956 | 11.02% | |
| RAPP |
Rapport Therapeutics, Inc.
Healthcare
|
Reduced | 1,784,517 | $53,000,154 | 10.69% | |
| CVRX |
CVRx, Inc.
Healthcare
|
Held | 4,103,430 | $33,114,680 | 6.68% | |
| LEGN |
Legend Biotech Corp
Healthcare
|
Held | 814,586 | $26,563,649 | 5.36% | |
| CTNM |
Contineum Therapeutics, Inc.
Healthcare
|
Held | 1,979,173 | $23,255,282 | 4.69% | |
| PRCT |
PROCEPT BioRobotics Corp
Healthcare
|
Held | 357,939 | $12,774,842 | 2.58% | |
| XNCR |
Xencor Inc
Healthcare
|
Held | 748,062 | $8,774,767 | 1.77% | |
| ARWR |
Arrowhead Pharmaceuticals, Inc.
Healthcare
|
Held | 247,598 | $8,539,655 | 1.72% | |
| FATE |
Fate Therapeutics Inc
Healthcare
|
Held | 3,379,064 | $4,257,620 | 0.86% | |
| LYEL |
Lyell Immunopharma, Inc.
Healthcare
|
NEW | 54,887 | $891,364 | 0.18% | |
| NNOX |
Nano-X Imaging Ltd.
Healthcare
|
Held | 158,852 | $587,752 | 0.12% | |
| LAB |
Standard Biotools Inc.
Healthcare
|
Held | 311,967 | $405,557 | 0.08% |